Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EyePoint Pharmaceuticals, Inc.
This retrospective study is intended to provide large-scale, real-world data on clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and Female subjects at least 18 years of age
Subjects who underwent cataract surgery from 12Mar2019 to 15Dec2019 and received DEXYCU
You may not be if
Subjects who underwent cataract surgery and did not receive DEXYCU
